Search

Saved articles

You have not yet added any article to your bookmarks!

Newsletter image

Subscribe to the Newsletter

Join 10k+ people to get notified about new posts, news and tips.

Do not worry we don't spam!

Eli Lilly and Novo Nordisk Vie for Dominance in India's Obesity Treatment Sector

Eli Lilly and Novo Nordisk Vie for Dominance in India's Obesity Treatment Sector

Post by : Saif Rahman

Global pharmaceutical giants Eli Lilly and Novo Nordisk are in a fierce contest to capture the expanding market for obesity medications in India. With millions of potential patients and the introduction of cheaper generic alternatives on the horizon for next year, both firms are swiftly maneuvering to establish dominance in this promising healthcare landscape.

By 2050, India is projected to host the second-largest population of overweight or obese individuals globally. Though obesity treatments remain costly and largely out-of-pocket for consumers, the demand is escalating. According to analysts, the Indian market for obesity drugs could surpass $1 billion within the next two years, marking it as a strategic target for international pharmaceutical players.

Lilly enjoys an early lead thanks to the earlier launch of its drug Mounjaro compared to Novo Nordisk's Wegovy. Mounjaro has rapidly become the leading obesity medication by revenue soon after its introduction, credited to its efficacy in weight loss and its timely market entry.

In response, Novo Nordisk has taken proactive measures. The company reduced the price of Wegovy by up to 37% last November to enhance accessibility and compete effectively. Additionally, it introduced its diabetes medication Ozempic in India at a more competitive rate. Novo’s head in India emphasized the importance of affordability in this cost-sensitive market.

The rivalry is expected to heighten further in March 2026, when patents for semaglutide, the key component in Wegovy and Ozempic, will expire. Over 20 Indian manufacturers are poised to introduce lower-cost generic options that analysts predict could be available at 60% less than current prices. This scenario could present a significant challenge for Novo, while Lilly stands to gain from extended patent protection for Mounjaro well into the next decade.

Both companies are also focused on expanding their market presence. Lilly has collaborated with Cipla to release an additional formulation of its drug aimed at smaller communities, along with partnerships with Apollo Hospitals to increase awareness regarding obesity and diabetes. Furthermore, the firm is heavily investing in manufacturing facilities in India.

Novo Nordisk is taking similar steps by partnering with Emcure Pharmaceuticals and launching a new semaglutide brand to enhance distribution efforts. The company is also aligning with digital health platforms and hospitals to provide patient support and promote awareness.

Given the ban on direct advertising of prescription medications in India, both companies are executing extensive public initiatives to inform citizens about obesity as a health condition. Utilizing billboards, newspaper advertisements, and wellness clinics, they encourage people to seek medical guidance rather than dismiss obesity as merely a lifestyle issue.

As the interest in weight-loss solutions extends beyond urban centers into smaller towns and middle-class households, the competition between Lilly and Novo intensifies. The results of this rivalry will ultimately influence the treatment landscape for obesity in India and the affordability of these transformative therapies in the years to come.

Dec. 24, 2025 2:49 p.m. 253

#Global News

Klang Flash Floods Disrupt Traffic Across Selangor, Malaysia
Nov. 18, 2026 11:37 a.m.
Heavy rain causes Klang flash floods, disrupting traffic in Bukit Raja and Shah Alam as motorists face delays across Selangor, Malaysia
Read More
Xi Jinping Urges Asia-Pacific Nations to Remove Trade Barriers
Nov. 18, 2026 10:20 a.m.
Xi Jinping urges Asia-Pacific economies to remove trade barriers, boost investment and strengthen regional stability at the APEC Summit in China
Read More
Singapore Reviews New US Chip Export Controls Targeting China
Nov. 17, 2026 11:34 a.m.
Singapore reviews US chip export restrictions targeting China's AI access, raising concerns for semiconductor trade and data centre businesses
Read More
APEC Members Emphasise Safe and Responsible Use of Artificial Intelligence
Nov. 17, 2026 10:24 a.m.
APEC members discuss responsible AI use, digital innovation and data governance as China and the US compete for global AI leadership
Read More
Union of European Clubs Challenge UEFA and EFC Over EU Competition Rules
Nov. 16, 2026 5:18 p.m.
UEC files an EU competition complaint against UEFA and EFC, challenging club representation, governance rights and decision-making powers
Read More
US Dollar Extends Rally as Yen Faces Pressure After Weak GDP
Nov. 16, 2026 4:29 p.m.
The US dollar reaches a 19-month high as traders assess Fed rate signals, weak Japan GDP data and possible yen intervention
Read More
Sheikh Hasina Plans December Return to Bangladesh Despite Death Threat
Nov. 16, 2026 3:35 p.m.
Sheikh Hasina plans to return to Bangladesh in December despite death threats, a death sentence and growing political tensions with Dhaka
Read More
Trump Plans to Name Nvidia and AI Firms US National Champions
Nov. 16, 2026 10:01 a.m.
Trump administration plans to name Nvidia, Amazon, Microsoft and OpenAI among US AI national champions to expand overseas and compete with China
Read More
Mohammed Shami Retires From Test Cricket, Eyes White-Ball Career
Nov. 7, 2026 11:10 a.m.
Mohammed Shami retires from Test cricket after 13 years, with 229 wickets. He will continue playing white-ball cricket and domestic matches
Read More
Trending News